Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free GRDX Stock Alerts

Entero Therapeutics (GRDX) Competitors

$6.35 +0.29 (+4.79%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$6.50 +0.16 (+2.44%)
As of 06/5/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GRDX vs. BTMD, FLNA, CTOR, XBIT, and MCRB

Should you buy Entero Therapeutics stock or one of its competitors? MarketBeat compares Entero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entero Therapeutics include biote (BTMD), Cassava Sciences (FLNA), Citius Oncology (CTOR), XBiotech (XBIT), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

How does Entero Therapeutics compare to biote?

Entero Therapeutics (NASDAQ:GRDX) and biote (NASDAQ:BTMD) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

biote has a net margin of 8.29% compared to Entero Therapeutics' net margin of 0.00%. biote's return on equity of -25.72% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero TherapeuticsN/A -49.81% -11.02%
biote 8.29%-25.72%15.12%

Entero Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, biote has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

biote has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero Therapeutics$40K1,055.69-$6.39M-$1.88N/A
biote$192.22M0.46$27.05M$0.445.32

biote has a consensus target price of $2.75, indicating a potential upside of 17.52%. Given biote's stronger consensus rating and higher possible upside, analysts plainly believe biote is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
biote
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, biote had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for biote and 0 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.00 equaled biote'saverage media sentiment score.

Company Overall Sentiment
Entero Therapeutics Neutral
biote Neutral

Summary

biote beats Entero Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Entero Therapeutics compare to Cassava Sciences?

Entero Therapeutics (NASDAQ:GRDX) and Cassava Sciences (NASDAQ:FLNA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Entero Therapeutics has higher revenue and earnings than Cassava Sciences. Entero Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero Therapeutics$40K1,055.69-$6.39M-$1.88N/A
Cassava SciencesN/AN/A-$90.97M-$1.61N/A

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 278.79%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cassava Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Entero Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.71, meaning that its share price is 171% less volatile than the broader market.

In the previous week, Cassava Sciences had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for Cassava Sciences and 0 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.00 beat Cassava Sciences' score of -0.35 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Entero Therapeutics Neutral
Cassava Sciences Neutral

Entero Therapeutics' return on equity of -49.81% beat Cassava Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero TherapeuticsN/A -49.81% -11.02%
Cassava Sciences N/A -53.90%-34.20%

Summary

Cassava Sciences beats Entero Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Entero Therapeutics compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Citius Oncology has a beta of 3.41, suggesting that its stock price is 241% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

Entero Therapeutics' return on equity of -49.81% beat Citius Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Citius OncologyN/A -99.47% -42.16%
Entero Therapeutics N/A -49.81%-11.02%

Entero Therapeutics has higher revenue and earnings than Citius Oncology. Entero Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Citius OncologyN/AN/A-$24.76M-$0.47N/A
Entero Therapeutics$40K1,055.69-$6.39M-$1.88N/A

Citius Oncology presently has a consensus target price of $6.00, suggesting a potential upside of 669.23%. Given Citius Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Citius Oncology is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Oncology
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 7.8% of Citius Oncology shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Citius Oncology had 3 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Citius Oncology and 0 mentions for Entero Therapeutics. Citius Oncology's average media sentiment score of 0.25 beat Entero Therapeutics' score of 0.00 indicating that Citius Oncology is being referred to more favorably in the media.

Company Overall Sentiment
Citius Oncology Neutral
Entero Therapeutics Neutral

Summary

Citius Oncology beats Entero Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Entero Therapeutics compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Entero Therapeutics has higher revenue and earnings than XBiotech. Entero Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotechN/AN/A-$45.54M-$1.32N/A
Entero Therapeutics$40K1,055.69-$6.39M-$1.88N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XBiotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, XBiotech's average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score.

Company Overall Sentiment
XBiotech Neutral
Entero Therapeutics Neutral

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

XBiotech's return on equity of -26.10% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XBiotechN/A -26.10% -25.06%
Entero Therapeutics N/A -49.81%-11.02%

XBiotech has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Summary

XBiotech beats Entero Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Entero Therapeutics compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Seres Therapeutics has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres Therapeutics$790K81.24$5.70M-$5.17N/A
Entero Therapeutics$40K1,055.69-$6.39M-$1.88N/A

Entero Therapeutics' return on equity of -49.81% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Seres TherapeuticsN/A -130.29% -35.35%
Entero Therapeutics N/A -49.81%-11.02%

Seres Therapeutics currently has a consensus target price of $22.00, suggesting a potential upside of 231.83%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Seres Therapeutics is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seres Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Seres Therapeutics has a beta of 0.13, suggesting that its share price is 87% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

In the previous week, Seres Therapeutics had 4 more articles in the media than Entero Therapeutics. MarketBeat recorded 4 mentions for Seres Therapeutics and 0 mentions for Entero Therapeutics. Seres Therapeutics' average media sentiment score of 0.65 beat Entero Therapeutics' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Seres Therapeutics Positive
Entero Therapeutics Neutral

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Seres Therapeutics beats Entero Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRDX vs. The Competition

Export
MetricEntero TherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$42.25M$992.66M$4.83B$11.99B
Dividend YieldN/A4.84%9.65%5.55%
P/E Ratio-3.381.4821.6923.62
Price / Sales1,055.69127.97174.39112.45
Price / CashN/A20.0646.3954.60
Price / Book0.867.8827.926.35
Net Income-$6.39M-$4.04M$109.80M$337.59M
7 Day Performance13.19%-2.30%0.56%-2.51%
1 Month Performance148.05%5.62%0.07%-0.69%
1 Year PerformanceN/A106.61%12.30%25.37%

Entero Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRDX
Entero Therapeutics
0.5751 of 5 stars		$6.35
+4.8%		N/AN/A$42.25M$40KN/A9
BTMD
biote
2.9007 of 5 stars		$2.00
-2.0%		$2.75
+37.5%		-36.2%$75.16M$188.16M4.55194
FLNA
Cassava Sciences
1.7467 of 5 stars		$1.54
-0.6%		$5.00
+224.7%		-37.7%$74.39MN/AN/A20
CTOR
Citius Oncology
2.208 of 5 stars		$0.80
-1.1%		$6.00
+651.9%		-19.6%$74.20MN/AN/AN/A
XBIT
XBiotech
0.3645 of 5 stars		$2.42
-0.8%		N/A-17.1%$73.78MN/AN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GRDX) was last updated on 6/6/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
How to get into the SpaceX IPO before June 12
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel